

6th International Conference on
CARDIOLOGY HEART DISEASE AND HEART FAILURE

September 19, 2022 | Webinar

Submitted Date: 11-08-2022 | Accepted Date: 13-08-2022 | Published Date: 15-10-2022

Investigation of the molecular mechanisms underlying the antiatherogenic actions of kaempferol in human THP-1 macrophages

Maha Majeed Ayoub

King Abdulaziz University, Saudi Arabia

The major cause of mortality worldwide is cardiovascular disease (CVD) (WHO, 2015). Atherosclerosis, hardening and narrowing of arteries, caused by accumulation of fatty acids and lipids (cholesterol plaques) is a main reason of stroke, myocardial infarction and angina. Present therapies basically use statins like β -Hydroxy β -methylglutaryl-CoA for cardiovascular disease showed less than 70% efficacy and multiple side effects. To evaluate the impact of kaempferol, a natural medication, against an atherosclerotic cell model, we undertook an *in vitro* investigation. The researchers used cytotoxicity assays, Boyden chamber invasion assays and quantitative real-time PCR. Affymetrix microarrays were used to profile the entire transcriptome of kaempferol-treated cell lines and Partek Genome Suite was used to interpret the results. THP-1 macrophages were not cytotoxic to kaempferol. In comparison to the control, kaempferol reduced monocyte migration mediated by monocyte chemoattractant protein 1 (MCP-1) by 80%. MCP-1 (73.71-fold) and intercellular adhesion molecule 1 (ICAM-1, 2.47-fold) expression were both reduced in kaempferol-treated cells, according to qPCR results. For IFN- γ and IFN- γ + kaempferol-treated cells, we found 295

and 168 differentially expressed genes (DEGs), respectively. According to DEG pathway analysis, kaempferol exhibits anti-atherosclerosis and anti-inflammatory characteristics. Kaempferol is an effective and safe therapy for atherosclerosis.

References

1. Lusis, AJ. Atherosclerosis. Nature 2002, 407, 233-241.
2. McLaren, J.; Michael, D.; Ashlin, T.; Ramji, D. Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapy. Prog. Lipid Res. 2011, 50(4), 331-47.
3. Ramji, D.; Davies, T. Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev. 2015, 26(6), 673-85.

Biography

Maha Majeed Ayoub is in cell culture unit and experimental biochemistry unit, King Fahd medical research centre, King Abdulaziz university, Jeddah 21589, Saudi Arabia.

ma_ha@hotmail.com